California Oncology Weekly
"Where California Oncologists Go For Answers!"
A collaborative publication of the
Medical Oncology Association of Southern California, Inc.
 and the 
Association of Northern California Oncologists, Inc.
 

October 13, 2015  

California News

- Attached please find the quarterly CMA Federal Update to the Board of Trustees.
  • Congress passed legislation to avert the government shutdown and keep the government running until December 11, 2015. 
  • Health Care Issues in the Presidential Campaign.  On October 7, the LA Times ran an excellent article by Noam Levy framing the health care issues in the 2016 Presidential Election. http://www.latimes.com/nation/politics/la-na-politics-healthcare-campaign-20151007-story.html
  • New Medicare Payment Programs Adopted by Congress. The CMA summary of the Medicare SGR Payment Reform legislation H.R. 2 "The Medicare Access and CHIP Reauthorization Act" (called MACRA) that Congress passed earlier this year. While most physicians know that the Medicare SGR payment formula was repealed, many are not aware that the legislation establishes new payment systems and quality programs which begin in 2019.  Please meet with your Members of Congress and urge them to Cosponsor HR 3309 the Meaningful Use Reform legislation and HR 2568 the Medicare RAC Audit Reform legislation.  It is crucial that we build support for these time-sensitive bills before the penalties take effect.  The CMA hand-out for your Member of Congress is also attached. MACRA CMA Summar
- While regulatory approval of Blue Shield of California's $1.2 billion acquisition of the Los Angeles managed-care company Care1st removed its state tax-exempt status, consumer groups say the combined entity's commitment to expand access and increase transparency doesn't go far enough.  Read More 
 
- October is Breast Cancer Awareness Month.
- Governor Brown has signed AB374 into law. AB374 will permit a prescribing physician to request a step therapy override determination from a health plan or insurer on behalf of a patient if doing so is in the best interest of the patient.
 
- The open enrollment period for the third year of Covered California, California's health benefit exchange, begins November 1, 2015, and continues through January 31, 2016. All 10 health insurance companies that offered coverage in 2015 will continue to offer coverage in 2016, with two new health insurance companies, United Healthcare (UHC) and Oscar, entering into the marketplace for 2016 in select regions.
 
- The next Cal/OSHA Antineoplastic Drugs Advisory Meeting will be on Wednesday, October 28, 2015. The meeting will be in Oakland at the Elihu Harris State Building on 1515 Clay Street in Room 1304 on the 13th floor, from 10:00AM to 3PM.  The purpose of the meeting is to seek advice on a new discussion draft that is intended to meet the requirements of AB 1202 and is in response to the advice provided during the first meeting earlier. This bill would require the California Occupational Safety and Health Standards Board within the Department of Industrial Relations to adopt a standard for the handling of antineoplastic drugs, as defined, in health care facilities regardless of the setting. The bill would require the standard to be consistent with and not exceed specific recommendations adopted by the National Institute for Occupational Safety and Health for preventing occupational exposures to those drugs in health care settings. By creating a new crime, this bill would impose a state-mandated local program.
The agenda for the meeting, the discussion draft and related handouts will be sent out prior to the meeting and will also be posted on Cal/OSHA's website at: http://www.dir.ca.gov/dosh/doshreg/Antineoplastic-Drugs/
If you have questions regarding this meeting, please contact Grace V. Delizo Senior Safety Engineer, DOSH Research and Standards Health Unit, at 619-278-3770 or Bob Nakamura at 510-286-7005. Thank you for your interest in this project.

- CMA's Practices Resources (October 2015) is now available online at 
 and features articles entitled: Like it or not, ICD-10 is here--what practices need to know; Medi-Cal identifies and fixes system issue; CMS releases 2014 PQRS and QRUR reports: opens formal review period;
Noridian announces web-based provider enrollment workshops; Medicare reminder: SNF consolidated billing; Reminder:
Blue Shield fee schedule change effective November 1; Reminder: UHC to require prior authorization for several outpatient procedures on October 1; Ask the Expert: How long do I have to refund a patient?; The Coding Corner: Question modifier 25 denials. 

- UnitedHealthcare's Network Bulletin (October 2015) is now available online and features articles entitled: Link--your new gateway to UnitedHealthcare's online tools; The UnitedHealthcare Premium Designation Program; ICD-10 implementation. Go to  for more information.



Noridian News

- Following, please find links to the various MolDX policies to be discussed at the Noridian CAC meeting, next week, October 21st. Please take a look at them. Is this acceptable to oncology? Oncology has an opportunity to comment and make change, if necessary. Please send you comments to the MOASC Office moasc@moasc.org by THIS FRIDAY, October 16th, so we can get our comments to Noridian prior to the meeting.  Thank you for your attention to this request. The LCDs are also hyperlinked to the Medicare Coverage Database:

Note: The ICD-10 codes for male breast cancer were erroneously included in the current draft LCD and will be removed when the LCD finalizes since Prosigna is not currently approved for use in the male breast cancer patient.
Note: This LCD will be updated when it finalizes to include CPT 81479 for billing of this service.          
                  
If the hyperlink for the LCD titles above will not open by just clicking on it, right click on the title of the LCD which opens a pop-up box. Select "Open Hyperlink".

-
Noridian/JEMAC has posted the following updates to its website (http://med.noridianmedicare.com/web/jeb):
* MLN Connects Provider eNews
ICD-10--Coding around the Compliance Date; Physician Orders for Lab, Radiology Services, and Other Services after ICD-10 Implementation; Access the ICD-1o Code Setl Finding ICD-10 Information Online; Get ICD-10 Answers in One Place; 5 Ways to Check Your Claim Status
* Announcements--CMS Proposes New Medicare Clinical Diagnostic Laboratory Tests Fee Schedule; MACRA: New Opportunities for Medicare Providers through Innovative Payment Systems; Getting Started with the Hospice Item Set: Update Fact Sheet Available
* Medicare Learning Network Educational Products--Medicare Enrollment and Claim Submission Guidelines Booklet-Revised; Medicare Enrollment for Institutional Providers Fact Sheet-Revised
* CCI Edits, Version 22.0, Effective January 1, 2016 CR9326
* ASP Medicare Part B Drug Pricing Files-January 2016 CR9351
* ICD-10 Conversion/Coding Infrastructure Revisions to NCDs-3rd Maintenance CR9252
* ICD-10 Part B Claims Processing and Remittance Advice Messages
* ICD-10 Workshop (October 22, 2015)
* Outpatient Therapy Services Workshop (October 29, 2015)
 
- Join Noridian at the upcoming Ask the Contractor Teleconference (ACT), Thursday, October 15, 2015, 1:00-2:00 p.m. Pacific Time. Call 866-243-8959.Noridian representatives from various departments including Appeals, Claims Processing, Electronic Data Interchange Support Services (EDISS), Medical Review (MR), Provider Contact Center (PCC), Provider Enrollment, Provider Outreach and Education (POE), and System Support will be available to address your questions. No registration is required for this call. Please call in ten minutes prior, the call will start promptly at 1:00pm. After placing the call, you will be asked for the following:
Conference Name; Facility Name; Location; Number of people in attendance. ACTs are designed to open communication between providers and Noridian, which allows for timely identification of problems, and sharing information in an informal and interactive question and answer (Q&A) format. No Personal Health Information (PHI) is allowed.  Noridian has created the "Ask the Contractor Teleconference Question Submission Form" which can be used to submit questions up to five days prior to the ACT. Questions submitted using this form will be answered first during the ACT; lines will then be opened as time allows. Do not include any PHI or claim specific inquiries on this form. If you have claim specific questions, contact the Provider Contact Center. Providers will need to have Version 7 or higher of Adobe Reader to use this form. Q&As will be posted on the Noridian website at Ask the Contractor Teleconference (ACT). Noridian looks forward to your participation.
 
 

DHCS/Medi-Cal News
 
- The next DHCS Stakeholder Advisory Committee (SAC) meeting will be held on Wednesday, October 14, 2015, from 9:30 a.m. to 3:30 p.m. at the Sacramento Convention Center. There is also a listen-only conference line to hear the meeting:  888-968-3517, passcode 8245294. The agenda for the October 14, 2015, SAC meeting and the summary of the July 22, 2015, meeting can be found at the link below.  Additional materials will be available on the DHCS website by October 9. All meeting materials can be found on the SAC website: http://www.dhcs.ca.gov/Page/DHCSStakeholderAdvisoryCommittee.aspx.  
There will be public comment at the end of the meeting.
             

  
 MOASC News
   
- In preparation for discussion with Noridian at the next CAC meeting on October 21st, MOASC seeks input from membership regarding the impact of ICD-10 on your practice. As we have the ear of Noridian, and a few weeks of ICD-10 coding completed, MOASC wishes to represent you on this timely issue. Please send your ICD-10 concerns to moasc@moasc.org for MOASC President, Warren Fong, M.D., to take on your behalf. Thank you
 
- Please join MOASC's LuncthTime Series  presentation on "Biosimilar Clinical and Legislative Updates for Physicians and Clinical Staff." The webinar is on October 28th at 12:00pm, and is being sponsored by Sandoz Biopharmaceuticals. Please RSVP to the MOASC Office at moasc@moasc.org.
 
- You are invited to the MOASC Administrator Meeting, November 5, 2015, 8:00am to 3:00pm at The Mission Inn, Riverside. At this final meeting of the year, you'll hear from key industry stakeholders how the industry is faring with implementation of the new code sets. Take this unique opportunity to learn from industry experts, what they know to keep your practice current and trending toward success. Discuss with colleagues what the initial impact of ICD-10 has had on operations.  Some of the topics include: Key data points for a practice's health, patient surveys, embezzlement and COPA; Current Trends in Oncology, USP 797/800, Patient Support, Medi-Cal and Medicare Updates. DON'T MISS THIS VALUABLE EVENT! If you wish to reserve a hotel room at a discounted rate, please contact the MOASC Office at moasc@moasc.org.
 
- MOASC is pleased to partner with Research to Practice for the Year in Review (YIR) Los Angeles meeting on Saturday, November 21. Please click on the link for more information. http://www.researchtopractice.com/Meetings/YIR2015/CA
 
- MOASC has openings on the Board of Directors. Physician Members who are interested in providing direction and assistance to your state oncology organization are encouraged to contact the MOASC Office at moasc@moasc.org.
 
- MOASC is also soliciting Administrators and Non-Physician Clinical Staff to fill the two positions on the board of Directors that represent your interests in the oncology practice. MOASC believes that the administrator and clinical staff bring fresh ideas and new points of view. Thank you for your participation & SUPPORT!
 
- California Partnership for Access and Treatment has notified MOASC of a great resource on the cost and value of prescription medicines. The link below is full of infographics that explain the role new medicines play in the overall reduction of health care costs. Please take a moment to review the document and please share with your patients. Prescription Medicines - Costs in Context
 
- Effective January 1, 2015, AB219 (the Health Care Coverage: Cancer Treatment Act) limits a patient's total co-payment and coinsurance for an oral cancer medication to $200 per 30-day supply. Some private payor pharmacy benefit plans may be in violation of the provision of AB219. If you are finding this to be the case with any payor or their PBM, please let the MOASC office know the name of the health plan and PBM company at moasc@moasc.org.Thank you.

- Member Issues:
The MOASC Office receives questions from the membership, and post if it affects all. Please read the following question and answer.
 
Q:"...I sometime see this comment from ICD-10:  ICD-10-CM E03.9 is grouped within Diagnostic Related Group(s) (MS-DRG v30.0):
The E03.9 is for Hypothyroidism, what is the highlighted in RED mean?   Please help..."
 
A: As ICD-10 codes are also used in hospitals, Diagnostic Related Groups, or DRG's, are used by hospitals to code in-patient occurrences only.  DRG's are not applicable to out-patient or physician practice billing. So, ICD-10 instructions will also have hospital notations along with physician and out-patient applicable notations. It is important to understand the difference. Thank you for your question!
 
If you have any questions, please do not hesitate to contact the MOASC Office at
 


Like us on Facebook   Follow us on Twitter   View our profile on LinkedIn



ANCO News
 
- ANCO's Molecular Diagnostics & Clinical Decision Making takes place at The Claremont Resort on October 24. Faculty from industry, payers, and local institutions will discuss the science of molecular diagnostics, reimbursement for molecular diagnostics, and the use of molecular diagnostics in clinical decision making using case studies. For more information, visit www.anco-online.org/MolDx.pdf.
 
ANCO's last Hematologic Malignancies Update for 2015 takes place on November 7, 2015. Join Brian A. Jonas, M.D., Ph.D., UC Davis, Michaela Liedtke, M.D., Stanford University, and Gregory P. Kaufman, M.D., Stanford University, to learn the latest about treatment modalities for acute leukemias, myelodysplastic syndromes, and myeloma and discuss case studies for each diagnosis. The program takes place at the Stanford Park Hotel in Menlo Park. Go to www.anco-online.org/4Q2015HemeMalig.pdf for more information.
 
- ANCO is pleased to be a sponsor of the 16th Multidisciplinary Management of Cancers: A Case-based Approach which returns to the Silverado Resort and Spa, Napa, on March 18-20, 2016. The meeting is presented in collaboration by the Stanford Cancer Institute, UC Davis Comprehensive Cancer Center, and UCSF Helen Diller Family Comprehensive Cancer Center. For more information, visit http://cme.stanford.edu/multicancers.

- Effective January 1, 2015, AB219 (the
Health Care Coverage: Cancer Treatment Act) limits a patient's total co-paym,went and coinsurance for an oral cancer medication to $200 per 30-day supply. It has been brought to ANCO's attention that some private payor pharmacy benefit plans may be in violation of the provision of AB219. Read more about and take ANCO's AB219 survey at www.anco-online.org/AB219Survey.pdf.
 
- Four seats on the ANCO
Board of Directors are up for election in 2015. ANCO seeks nominations for candidates to stand for election to these seats. This year's election will be conducted via mail ballot in December. Candidates with the top four vote totals will serve for three years (i.e., from 2016-2018, inclusive). The ANCO Board of Directors governs the Association, developing advocacy strategies and policies, approving educational meeting proposals and activities, and considering membership benefits. The Board meets in person approximately once each year in the San Francisco Bay Area and via bimonthly teleconference. Expenses associated with attending Board meetings are reimbursed. Communication with the Board is also conducted via FAX broadcast and e-mail. You may nominate an ANCO member (including yourself) to stand for election to the Board via FAX to the ANCO office at (415) 472-3961 or e-mail to execdir@anco-online.org no later than November 13, 2015.



MOASC Purchasing Network News 

- The mission of MPN Precision Medicine Advisory Board is to serve as an expert resource for the California oncology community in order to assist healthcare providers with education, guidance, and access to genomic molecular information in order to reach a consensus on practical definitions of clinical utility and to outline the information needed to form treatment strategies that target the molecular underpinnings of the specific disease in each patient. MPN has a unique opportunity to educate, guide, and launch a statewide dialogue among all stakeholders in order to reach a consensus on practical definitions of clinical utility and to outline the information needed by payers to support reimbursement for fully informative genomic profiling assays used in targeted cancer therapy. MPN and Foundation Medicine will be offering a series of educational webinars to assist healthcare providers and their support teams with education, guidance, and access to genomic molecular information.
DON'T MISS THE FOLLOWING OPPORTUNITIES TO LEARN MORE!
October 22nd @ 12:00 pm (PST)
Defining Clinical Utility
.
Please contact Lesli D. Lord at 214.578.9589 Lord.Lesli@gmail.com for more information.



National News

- Before departing for a week long recess, on October 9th the House Budget Committee marked up a reconciliation package that repeals five key portions of the Affordable Care Act. The package, which repeals the individual and employer mandates, several Affordable Care Act taxes that are unpopular with industry groups, and the Independent Payment Advisory Board, is expected to receive a floor vote in the House this month.
- TRICARE Beneficiary Bulletin #324.  Listen to this week's podcast to hear about: Prior Authorization and the New Pharmacy Law. Visit the TRICARE Media Center at www.tricare.mil/podcast. 



CMS News 

- On Thursday, October 15; 10:30-12pm Pacific Time, MLN Connects National Provider Call will provide an overview of the 2014 Supplemental Quality and Resource Use Reports (QRURs); confidential feedback reports for medical group practices and solo practices on resource utilization for Fee-For-Service episodes of care. The 2014 Supplemental QRURs report on 26 major episode types and an additional 38 episode subtypes, resulting in 64 total reported episode types. The 2014 Supplemental QRURs are for informational purposes only. Learn more about the reports on the 
Supplemental QRURs and Episode-Based Payment Measurement web page. To Register: Visit MLN Connects Event Registration. Space may be limited, register early. The call will be more meaningful if you have your 2014 Supplemental QRUR in front of you to follow along. Visit How to Obtain a QRUR and access your report prior to the call.

- CMS published a request for information to guide the implementation of the
Medicare and CHIP Reauthorization Act of 2015. Using these comments and the requirements of the law, CMS will craft change to the pay-for-reporting, pay-for-performance, and electronic health record incentive programs as well as define alternative payment models at www.federalregister.gov/articles/2015/10/01/2015-24906/request-for-information-regarding-implementation-of-the-merit-based-incentive-payment-system. In addition, CMS has issued a request for information (RFI) regarding implementation of the Merit-based Incentive Payment System (MIPS), promotion of alternative payment models (APMs), and incentive payments for participation in eligible APMs. The questions in the RFP aim to address the challenges that may arise wit MACRA implementation. These questions are important to the oncology community as they seek to define alternative payment models for health providers, and how to improve quality measures and meaningful use requirements. 

- Medicare SGR Payment Reform legislation H.R. 2 "The Medicare Access and CHIP Reauthorization Act" (called MACRA) was effective on October 1, 2015, so the CMS posted a Request for Information (RFI) on the new payment systems.  While the new payment systems do not take effect until 2019, CMS was mandated by the legislation to involve physicians in defining quality and clinical improvement, and designing the new payment systems.  None of it is defined in the law.  Thus, CMS is seeking early input from the physician community to start development of the new programs.  Comments are due on October 30.  The law poses an incredible opportunity for physicians, not government bureaucrats, to develop payment models and define quality and clinical improvement. 
 
- In 2016, CMS will apply a negative payment adjustment to individual eligible professionals (EPs) that did not satisfactorily report PQRS in 2014. Individuals and groups that receive the 2016 negative payment adjustment will not receive a 2014 PQRS incentive payment. EPs, CPC practice sites, PQRS group practices, and ACOs that believe they have been incorrectly assessed the 2016 PQRS negative payment adjustment may submit electronically via the Quality Reporting Communication Support Page (CSP),  an informal review between September 9, 2015 and November 9, 2015 at 8:59 p.m. Pacific Time, requesting CMS investigate incentive eligibility and/or payment adjustment determination. All informal review requestors will be contacted via email of a final decision by CMS within 90 days of the original request for an informal review. All decisions will be final and there will be no further review.   Please see 2014 Physician Quality Reporting System (PQRS): Incentive Eligibility & 2016 Negative Payment Adjustment - Informal Review Made Simple (available on the Analysis and Payment section of the PQRS website) for more information. For additional questions regarding the informal review process, contact the QualityNet Help Desk at 1-866-288-8912 (TTY 1-877-715-6222) or Qnetsupport@hcqis.org Monday-Friday from 7:00 a.m. to 7:00 p.m. Central Time. To avoid security violations, do not include personal identifying information, such as Social Security Number or Taxpayer Identification Number (TIN), in e-mail inquiries to the QualityNet Help Desk. 
 
- CMS has posted a new data set as part of the Provider Utilization and Payment files. This data set, called Referring Provider Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) Public Use File (PUF), provides information on physicians and other healthcare professionals who referred DMEPOS products and services for Medicare beneficiaries. The Referring Provider DMEPOS PUF contains information on utilization, payment (allowed amount and Medicare payment), and submitted charges organized by National Provider Identifier (NPI), Healthcare Common Procedure Coding System (HCPCS) code and supplier rental indicator. This PUF was created from CMS administrative claims data for Medicare beneficiaries enrolled in the fee-for-service program available from the CMS Chronic Condition Data Warehouse (www.ccwdata.org). CMS protects beneficiaries' personal information in all its data releases.  The data in the Referring Provider DMEPOS PUF covers calendar year 2013 and is based on information from Part B non-institutional DMEPOS claims. To view a fact sheet on the Referring Provider DMEPOS PUF, visit: 
 
 
   
Affiliate Association News
 
- You're invited! Please consider joining NCCN in San Francisco, CA for the NCCN 10th Annual Congress: Hematologic Malignancies™, October 16 - 17, 2015.
This year's agenda includes 13 educational sessions featuring the latest advances in hematologic malignancies, plus interactive Patient Case Studies & Panel Discussions where panelists will review and discuss interesting and challenging cases with the audience. Additionally, there is the addition of a Lunch Satellite Session titled, The NCCN Value Initiative: Using NCCN Evidence Blocks™ in Clinical Decisions. This session will feature the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Chronic Myelogenous Leukemia with NCCN Evidence Blocks™ and will take place October 17th, from 11:45 am to 1:00 pm. This session is open to all registered congress attendees. View the agenda for additional details on session topics and faculty. Reserve your spot today and save! 
 
- ACCC's 32nd National Oncology Conference: The "How-To" Conference for the Cancer Care Team takes place on October 21-23 in Portland. Register at
 
- Research to Practice for the Year in Review (YIR) Los Angeles meeting is on Saturday, November 21. Please click on the link for more information.
 
- Don't wait to register now to ensure the best available housing for the premier event in hematology! ASH invites you to attend the 57th ASH Annual Meeting and Exposition from December 5-8, 2015, at the Orange County Convention Center in Orlando, FL. This year's meeting will debut some new offerings and continue to showcase the full spectrum of hematology, from discoveries to new therapies to outcomes analyses. Register as an individual.
Register as a group. To register as an individual, you must sign in using your current ASH username (moasc@moasc.org) and password.
 
- ASCO has announced a new study which provides compelling evidence that a simple tool can help predict which patients with cancer may be in their final year of life. The tool, known as the Surprise Question, was found to predict the risk of cancer death within one year better than factors such as cancer type or stage alone. This study will be presented at the upcoming 2015 Palliative Care in Oncology Symposium in Boston.  read press release 
 
ASCO's Practical Tips for the Oncology Practice(6th Edition) is now available at 
www.asco.org in eBook format.
 
- Be a part of ASCO's new collaborative learning network, PracticeNET, to gain valuable insights into your practice's business operations and quality of care. This new initiative, from ASCO's newly formed Clinical Affairs Department, uses existing data from your practice management system to offer customizable reports that measure practice-wide and individual performance against a national database of other PracticeNET participants. For more information, and to enroll, visit
asco.org/practicenet. 
 
- COA PAC is a political action committee (PAC) founded by community oncologists for community oncology. Funds raised within COA PAC are used to contribute to campaigns of individuals seeking elected office to the United States Senate and House of Representatives. COA PAC supports individuals who have demonstrated an interest in community cancer care and in preserving and enhancing the nation's cancer care delivery system for cancer patients.
A suggested initial contribution is at least $1,000; however, many oncologists have made an initial contribution of $2,000. Contributions cannot exceed $5,000 per year. COA PAC has a Community Oncology Leadership Club that recognizes contributions. If you want elected officials who support community oncology and the patients served, you need to support their election campaigns. COA PAC is the only independent PAC dedicated solely to community oncology. Community oncologists need to be far more active as evidenced by the list below of the top 60 healthcare professional PACs in 2014. COA PAC ranked 51st, behind many other more specialized areas of medicine. COA PAC makes the most of the funds raised, but community oncology is lagging behind many other areas of medicine in making an impact. It is up to you and your fellow oncologists to contribute to increase support for community oncology. www.CommunityOncology.org
    
- The National Comprehensive Cancer Network (NCCN) is making available the NCCN Scale in October. The NCCN Scale is a tool to aid cancer patients make more informed choices by helping to assess the costs of medical treatments juxtaposed against their benefits. The NCCN Scale will make use of the so-called evidence blocks that "assign a score of up to five points for each of five measures--price, effectiveness, safety, quality and consistency of clinical data." In its October launch, the NCCN Scale will provide ratings for drugs used to treat multiple myeloma and chronic myeloid leukemia. Before 2016, the Scale is expected to have also included ratings for other types of cancer.


 
Industry News

- Bristol-Myers Squibb's Opdivo (nivolumab) receives expanded FDA approval in previously-treated metastatic non-small cell lung cancer (NSCLC), offering improved survival to more patients.
Opdivo is the only PD-1 inhibitor approved for previously treated metastatic squamous and now non-squamous NSCLC patients,whose disease progressed during or after platinum-based chemotherapy, regardless of PD-L1 expression. Opdivo represents the only PD-1 inhibitor approved by the FDA to deliver superior overall survival compared to chemotherapy, docetaxel, in previously treated metastatic NSCLC. Safety profile of Opdivo is consistent with prior studies. For more information please contact Dean Marcoccia  at Dean.Marcoccia@bms.com.     
 
- Eisai invites you to attend a live presentation of, "Treatment of Locally Recurring or Metastatic, Progressive Radio-active Iodine Refractory Differentiated Thyroid Cancer." October 22, 2015 at 6:00pm. Presented by Ezra Cohen, MD, Moores Cancer Center,University of California, San Diego. Please open this link for further information.
 
- Gilead Sciences is hosting a series of webcasts in support Blood Cancer Awareness Month through October 15. Learn more and register at https://classic.regonline.com/Register/Checkin.aspx?EventID=1748078. 
 
- During Breast Cancer Awareness Month last year, Pfizer released the results of a survey that showed the majority of Americans reported they know little to nothing about metastatic breast cancer (MBC), the most advanced stage of the disease which impacts 150,000-250,000 people in the U.S. alone. This year, Pfizer is launching a candid and inspiring social media campaign highlighting the stories and images of five women living with MBC. Visit the @StoryHalfTold Instagram account, www.StoryHalfTold.com, Facebook and Twitter, and SHARE using the hashtag #StoryHalfTold, #breastcancerawareness.

- Taiho Oncology informs ANCO and MOASC that the United States Food and Drug Administration has approved Lonsurf for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.




In This Issue
  1.  

 

 MOASC CALENDAR

 

LunchTime Series
October 28th  
November 18th

 

 

MOASC Administrator's Meeting

November 5th 

 

 

 

 

 

 

 

ANCO CALENDAR

   

NCCN's 10 Annual Congress:Hematological Malignancies
(October 16-17; San Francisco) 

 

(October 24; Oakland) 

 

(November 7; Palo Alto)

 

(January 7-9; San Francisco) 

 

ASCO's 2016 Cancer Survivorship Symposium 

(January 15-16; San Francisco)

 

(January 21-23; San Francisco) 

 

(March 18-20; Napa) 

 

 

 

 

 

 

 

 

 

 

 

 
The Medical Oncology Association of Southern California(MOASC) is a leading oncology society that advances and protects the ability of cancer patients to obtain, and the ability of the oncology physicians to provide, optimal cancer care. The Association of Northern California Oncologists (ANCO) is an association of hematologists/oncologists dedicated to promoting high professional standards of cancer care by providing a forum for the exchange of ideas, data, and knowledge. The material contained in the California Oncology Weekly is intended as general information for ANCO and MOASC members. Because diagnostic, treatment, contracting, coding, and billing decisions should be made on a case-by-case basis, any such information contained in the California Oncology Weekly may not apply in any given situation. Members are encouraged to contact their own consultants or advisors to obtain specific advice on matters relating to contracting, coding, and billing. The information contained in California Oncology Weekly should not be used as a substitute for such advice. This publication provides a summary of regulations affecting oncology and its business practices. Reading this newsletter does not substitute for understanding regulations and verifying the validity of every claim. This information is time-sensitive and is subject to change. MOASC or ANCO accepts no liability for any statements or articles herein.CPT codes are owned and trademarked by the American Medical Association.  All Rights Reserved.

 

  

MOASC: P.O. Box 161, Upland, CA 91785 | P (909) 985-9061 | F (909) 804-5006| www.moasc.org

ANCO: P.O. Box 151109, San Rafael, CA 94915 |  P (415) 472-3960 | F (415) 472-3961 | www.anco-online.org